Answers are grounded in this paper and cite their sources.
INTRODUCTION: Substance use disorders (SUDs) impose a substantial public health burden. In addition to behavioral therapies, pharmacological options are available for some SUDs. Repetitive transcranial magnetic stimulation (rTMS) is emerging as a therapeutic modality, but evidence on its benefits and tolerability when combined with pharmacotherapy remains limited. AREAS COVERED: This narrative review examines therapeutic rTMS alongside pharmacotherapy for addictive disorders. MEDLINE, Embase, PsycINFO, PubMed, and CENTRAL were searched from inception to 6 September 2026; PsycArticles, Web of Science, and Scopus were searched on 4 November 2026. Twenty-one studies, including 12 controlled comparisons, were synthesized descriptively. Controlled behavioral benefits were concentrated in tobacco studies; craving and psychiatric outcomes were heterogeneous. Reported adverse effects were generally mild and transient, although safety reporting was incomplete. No study directly compared medication conditions during active rTMS, precluding conclusions about pharmacological synergy or optimal pairings. EXPERT OPINION: Integration into addiction services is promising but requires evidence of durable behavioral benefit. rTMS after medical stabilization during the transition from detoxification to rehabilitation, followed by continuing pharmacotherapy, warrants investigation. Future directions include optimizing medication regimens, stimulation protocols, maintenance, and targeting while evaluating substance use outcomes, treatment attendance, and safety to establish which combinations benefit which patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: